Background & Objectives
This study used the oncologist-surveyed data from the IMS LifeLink™ Oncology Analyzer database. This database uses a sample projection technique to create a representative sample for each country, based on oncologist survey results. Front-line patients aged ≥ 20 years and diagnosed with GBM (as judged by data collected through physician survey) during 2012 to 2014 in the EU-5 countries were included. Patient demographics, comorbidities, therapy type, treatment initiator, average dose, number of surgeries, and concomitant medications were descriptively examined for the EU-5, overall, and by individual country.
Methods
To our knowledge this is the first detailed investigation into the front-line treatment patterns of GBM across the five EU countries. The common front-line treatment for GBM was found to be surgery followed by temozolomide chemotherapy, consistent with the ESMO guidelines. However, there was significant variation across countries with regard to the frequency of surgery and type of surgery, comorbidities, chemotherapy initiator, and concomitant medications. This study should be considered "descriptive and directional" only with respect to the retrospective nature of the data collection. Further studies / registry investigations 8 could improve the scope and robustness of these results; however, given the low incidence and prevalence of GBM, gaining large patient numbers is a difficult task.
Conclusions
1. Fuentes-Raspall, R., Vilardell, L., Perez-Bueno, F., Joly, C., Garcia-Gil, M., Garcia-Velasco, A., & Marcos-Gragera, R. (2011 • Findings from this study enable us to understand the real world treatment patterns of GBM in EU-5 countries.
There is limited availability of real world treatment pattern investigations for EU countries. 4, 5, 6 • Surgery was performed in most of the patients in this front-line GBM population. There was a pattern of surgery that suggested that patients in France are more likely to not have tumor-removing surgery, but biopsy only. As the standard published by EANO states surgery should be undertaken for patients stable enough for it, the high rate of biopsy-only could be the result of a greater number of frail patients. However, patient age of diagnosis was similar across EU-5 countries and France had fewer patients with COPD (than Spain) and cardiac dysfunction (than Germany) suggesting that patients in France were not more infirmed than their counterparts in other countries. This suggests that the biopsy-only practice has an alternative and perhaps non-medical basis.
• Radiation and concomitant temozolomide therapy was the most commonly used treatment, which is consistent with the ESMO guideline. 2 Within the small percentage of patients receiving non-TMZ treatment, procarbazine, lomustine and vincristine (PCV regimen) was used most often in UK, and in this upfront setting, bevacizumab was used as monotherapy or combination therapy in all countries except for Italy. Although these alternate treatments are used in a limited patient group, the differences seen among countries is notable.
• Our findings revealed that there are some variations in GBM treatment across the EU-5 countries. For example, in UK temozolomide was not used as commonly as the other EU 4 countries. This is consistent with the NICE guideline where adjuvant chemotherapy (initiation of temozolomide after surgery) is not included as part of standard therapy in UK. 7
• This study has the following limitations:
-Switching and discontinuation could not be determined from the OA analyzer tool -Previous therapies and diagnosis require recall and therefore might lead to 'recall bias' -Physicians also may have inadvertently included fewer complicated patients in the database because reporting their data required more effort during the survey.
• Future research may implement a prospective study medical chart review design to overcome recall bias and possibly provide more detailed, comprehensive information on the treatment pattern of GBM patients including diagnostic test findings, symptomatic decline, steroid use, MRI changes, and other relevant varables.
Discussion
A total of 64,932 patients from Germany (24,577), France (12,574), Italy (11,676), UK (8, 427) , and Spain (7,698) were included. The majority were male (64%, except Germany was 50%) and >56 years (70%). Comorbidities were similar across countries, except COPD (5%, whereas Spain was 19%) and cardiac dysfunction (4%, whereas Germany was 21%) (Table 1, Figure 1 ).
Results
Surgical procedures including excision of lesion, craniotomy, and lobectomy were performed, on average, in 89% of patients, except in France (47%). However, French patients were more likely to have a Burr Hole biopsy (44%) versus the other 4 countries (average of 20%) ( Table 2) .
Results (cont'd)
17 More than half of the patients had at least one brain surgical procedure performed. Surgery is more prevalent in countries such as the UK (87% vs 73%, p= 0.0002) and Germany (84% vs 69%, p= 0.0004) compared to the other 4 countries' average. (Figure 2) After surgery, the majority of patients went on to chemo-radiation therapy with TMZ (91%). Except in the UK, TMZ was used, on average, for 82% of front-line patients. In UK, TMZ was used for 65% of front-line patients (Figure 4a ). The other treatments that were used are listed in Figure 4b . Lomustine/procarboplatin/vincristine combination was the second most used therapy in UK (1.8%), while in France and Italy, the second most used therapies were bevacizumab (2.5%) and fotemustine (2.3%). Bevacizumab was used in all countries except for Italy. In no country is bevacizumab indicated for front-line treatment of GBM.
Frequently used concomitant medications were corticosteroids, anti-emetics, and gastrointestinal medications ( Figure 5 ); however, their frequency varied across the countries. For example, corticosteroids were used more often in Spain compared to France (72% vs 29%, p<0.00001). Anti-emetics were used more commonly in Spain compared to the other EU 4 countries (67% vs 41%, p<0.00001).
Chemotherapy treatment for patients in the EU-5 countries except for UK was likely to be initiated by a radiotherapist (58%) or medical oncologist (23%). In the UK, treatment was initiated by a radiotherapist 90% of the time. (Figure 3) Funding for this study was provided by Celldex Therapeutics.
